Novo Nordisk to Slash 9,000 Jobs Globally in Major Restructuring, Aiming for $1.3 Billion in Savings by 2026

By / / Breaking News

Key Takeaways

  • Novo Nordisk (NVO) announced a global workforce reduction of 9,000 jobs, with 5,000 of those cuts in Denmark, as part of a significant restructuring effort.
  • The pharmaceutical giant aims to save approximately $1.3 billion (8 billion Danish crowns) annually by the end of 2026 through these measures.
  • The restructuring is a strategic response to intensifying competition, particularly from rival Eli Lilly (LLY), and a need to streamline operations and reinvest in core growth areas like diabetes and obesity treatments.
  • The company has also lowered its 2025 earnings forecast following these announcements, signaling a challenging period ahead.

Danish pharmaceutical powerhouse Novo Nordisk (NVO) has unveiled a sweeping global restructuring plan that includes the elimination of 9,000 jobs worldwide. The move is designed to streamline operations and generate substantial cost savings, with the company targeting approximately $1.3 billion (8 billion Danish crowns) in annual savings by the close of 2026.

Of the total job cuts, 5,000 positions are slated to be eliminated in Denmark, where the company has a significant presence. This strategic overhaul comes as Novo Nordisk faces mounting pressure from intensifying competition, most notably from its U.S. rival Eli Lilly (LLY), in the lucrative diabetes and obesity treatment markets.

The company stated that the reorganization is critical to accelerate decision-making and reallocate resources towards high-growth potential areas within its key therapeutic segments. This proactive measure follows a period where Novo Nordisk had already implemented a global hiring freeze and canceled new hire contracts as part of broader cost-cutting initiatives.

In conjunction with the restructuring announcement, Novo Nordisk has also revised its 2025 earnings forecast downwards, a move that reflects the anticipated one-off net costs of 8 billion Danish kroner associated with the restructuring program. The company's operating profit growth forecast at constant exchange rates (CER) has been adjusted to 4-10 percent, down from a previous 10-16 percent. This marks the second downward adjustment to its profit outlook within a short period, highlighting the challenges the company is navigating.

CEO Mike Doustdar emphasized the necessity of these difficult decisions for the company's long-term success, stating that the company needs to evolve its approach to become "faster and more agile" in a dynamic market environment. The savings generated from these cuts are expected to be reinvested into further strengthening its position in the diabetes and obesity treatment sectors.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top